In vivo CAR-T: toward scalable and programmable immunotherapy

“....challenges have catalyzed the emergence of in vivo CAR-T engineering as a fundamentally new approach to cellular immunotherapy.”

This article is part of our ‘Rising Stars’ series, giving a platform to the emerging leaders of the sector. In this series, we share the perspectives of fledgling thought-leaders, chosen by our Editorial Advisory Board members as future stars in their field.

Yu (Clay) Cao, Cell & Gene Therapy Insights Editorial Advisory Board member, had this to say about his Rising Star nominee:

“Kartika is an experienced immunologist and CAR-T scientist who brings a strong foundation in rigorous scientific training into the biotechnology industry. She has rapidly grown into an independent, fast-learning, and impactful scientific driver. During her time at Tessera Therapeutics, she contributed to the development of the company’s proprietary all-RNA Gene Writer platform for in vivo CAR-T, where she played a key role in advancing technical optimization and driving project progression. Her ability to integrate multidisciplinary advances into a coherent vision underscores her growing impact as an innovation leader.”

Please enter your email to access content Read now